Leicester is leading the development of the world’s first molecularly stratified umbrella study, Mesothelioma Stratified Therapy (MiST).
This trial will utilise a molecular profiling panel to identify patients who are eligible for treatment. The second step will be to stratify patients for treatment, based on molecular eligibility. Patients would receive up to four different treatments sequentially. The third step will be to utilise genomic interrogation of the original biopsy tissue to understand why patients respond (or not) to the trial drugs and if they respond, what factors eventually lead to the emergence of drug resistance.
MiST will be a flagship, Leicester-sponsored clinical trial. Initially located in a single centre, the expectation will be that the study will be able to expand to multiple UK centres, with the potential to add promising new treatment arms and additional molecular stratifications.
For more details, contact Mi*********@**********ac.uk.
